首页> 外文期刊>International medical journal: IMJ >Total flavonoid content and in vivo hypotensive effect of chloroform insoluble fraction of Centella asiatica leaf extract
【24h】

Total flavonoid content and in vivo hypotensive effect of chloroform insoluble fraction of Centella asiatica leaf extract

机译:总黄酮含量和Centaiatica叶提取物氯仿不溶性分数的体内低度效应

获取原文
获取原文并翻译 | 示例
           

摘要

Ministry of Health of Indonesia have developed an antihypertensive Jamu formula that contains Centella asiatica leaf through a program namely "Evidence based Jamu Development". Reportedly, the ethyl acetate and chloroform fractions of C. asiatica leaf exhibited in vivo antihypertensive activity. The study aimed to determine the total flavonoid content in chloroform insoluble fraction of C. asiatica leaf extract (CIFCA) and to evaluate the in vivo hypotensive effect on phenylephrine-induced hypertensive rats by non-invasive tail-cuff method. The results showed that CIFCA contained the total flavonoid of 1.19±0.01% which was equivalent to quercetin. This flavonoid fraction at dose of 50 mg/kg showed a potent in vivo hypotensive effect by lowering blood pressure up to 150% on phenylephrine-induced rats. The EDinf50/inf values, a parameter of drug potency, of these effects on systolic, diastolic, and mean arterial blood pressure were 27.7 ± 1.52; 29.50 ± 1.61; and 27.76 ± 1.08 mg/kg, respectively. In conclusion, chloroform insoluble fraction of C. asiatica leaf extract is potential to develop as an antihypertensive agent. Ministry of Health of Indonesia have developed an antihypertensive Jamu formula that contains Centella asiatica leaf through a program namely "Evidence based Jamu Development". Reportedly, the ethyl acetate and chloroform fractions of C. asiatica leaf exhibited in vivo antihypertensive activity. The study aimed to determine the total flavonoid content in chloroform insoluble fraction of C. asiatica leaf extract (CIFCA) and to evaluate the in vivo hypotensive effect on phenylephrine-induced hypertensive rats by non-invasive tail-cuff method. The results showed that CIFCA contained the total flavonoid of 1.19±0.01% which was equivalent to quercetin. This flavonoid fraction at dose of 50 mg/kg showed a potent in vivo hypotensive effect by lowering blood pressure up to 150% on phenylephrine-induced rats. The ED 50 values, a parameter of drug potency, of these effects on systolic, diastolic, and mean arterial blood pressure were 27.7 ± 1.52; 29.50 ± 1.61; and 27.76 ± 1.08 mg/kg, respectively. In conclusion, chloroform insoluble fraction of C. asiatica leaf extract is potential to develop as an antihypertensive agent.
机译:印度尼西亚卫生部已开发出一种抗高血压贾武公式,其中包含Centella Asiatica叶通过计划即“基于验证的Jamu发展”。据报道,在体内抗高血压活性中表现出乙酸乙酸乙酯和氯仿叶片。该研究旨在确定C. Asiatica叶提取物(CIFCA)的氯仿不溶性级分中的总类黄酮含量,并通过非侵入式尾袖法评价苯妥肾上腺素诱导的高血压大鼠的体内低度影响。结果表明,CIFCA含有1.19±0.01%的总黄酮,其等同于槲皮素。剂量为50mg / kg的这种类黄酮部分通过降低血压诱导的大鼠的血压可达150%的体内低血压效果。 ED& inf& 50& / inf&这些作用对收缩性,舒张性和平均动脉血压的价值,药物效力的参数为27.7±1.52; 29.50±1.61;和27.76±1.08 mg / kg。总之,C. Asiatica叶提取物的氯仿不溶性级分是开发为抗高血压剂的潜力。印度尼西亚卫生部已开发出一种抗高血压贾武公式,其中包含Centella Asiatica叶通过计划即“基于验证的Jamu发展”。据报道,在体内抗高血压活性中表现出乙酸乙酸乙酯和氯仿叶片。该研究旨在确定C. Asiatica叶提取物(CIFCA)的氯仿不溶性级分中的总类黄酮含量,并通过非侵入式尾袖法评价苯妥肾上腺素诱导的高血压大鼠的体内低度影响。结果表明,CIFCA含有1.19±0.01%的总黄酮,其等同于槲皮素。剂量为50mg / kg的这种类黄酮部分通过降低血压诱导的大鼠的血压可达150%的体内低血压效果。 ED 50值,药物效力的参数,对收缩,舒张性,平均动脉血压的这些影响为27.7±1.52; 29.50±1.61;和27.76±1.08 mg / kg。总之,C. Asiatica叶提取物的氯仿不溶性级分是开发为抗高血压剂的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号